This review explores how unconventional T cells like MAIT and iNKT cells interact with metabolite antigens in tumors, highlighting their potential in immunotherapy.
Key Points
Unconventional T cells respond to non-peptidic metabolite antigens via MR1 and CD1 pathways.
MAIT cells can become immunosuppressive in cancers like glioblastoma, reducing their efficacy against tumors.
This review highlights the importance of the tumor microenvironment in shaping T cell responses.
Emerging therapies targeting MR1 and CD1 show potential in enhancing anti-cancer immunity through unconventional T cells.